ライフサイエンスコーパス: exudative

1 MA) in consecutive naive eyes diagnosed with exudative age-related macular degeneration (AMD) in comp

2 a 27-year-old control, 1 from a 78-year-old exudative age-related macular degeneration (AMD) patient

3 Anastomotic vessels in exudative age-related macular degeneration (AMD) represe

4 ibutor to the development and progression of exudative age-related macular degeneration (AMD).

5 s complex surgery used to restore reading in exudative age-related macular degeneration (AMD).

6 f this pathway, are altered in patients with exudative age-related macular degeneration (AMD).

7 with focal vitreomacular adhesion (VMA) and exudative age-related macular degeneration (AMD).

8 IMPORTANCE Exudative age-related macular degeneration (ARMD) is the

9 ll layer (GCL) of eyes with nonexudative and exudative age-related macular degeneration (NEAMD and EX

10 rget SRH may augment anti-VEGF treatments in exudative age-related macular degeneration and other dis

11 horoidal neovascularization in patients with exudative age-related macular degeneration and suggested

12 ved intravitreous bevacizumab injections for exudative age-related macular degeneration between Janua

13 othelial growth factor (VEGF) injections for exudative age-related macular degeneration or macular ed

14 ses to deliver excellent visual outcomes for exudative age-related macular degeneration patients whil

15 ul analysis of randomized clinical trials on exudative age-related macular degeneration reveals appar

16 irty-seven B-scan images of 37 patients with exudative age-related macular degeneration were chosen r

17 Patients were enrolled with unilateral exudative age-related macular degeneration who had recei

18 ncluding proliferative diabetic retinopathy, exudative age-related macular degeneration, and retinopa

19 taract and macular edema secondary to either exudative age-related macular degeneration, diabetic mac

20 tiation of intensive ranibizumab therapy for exudative age-related macular degeneration, macular atro

21 vein occlusion, retinopathy of prematurity, exudative age-related macular degeneration, sickle cell

22 the use of aflibercept for the treatment of exudative age-related macular degeneration.

23 igment, and 10.32 (95% CI: 0.83, 128.58) for exudative age-related maculopathy.

24 Diagnoses included severe (exudative) age-related macular degeneration (AMD) (12),

25 In eight exudative AMD (EX-AMD) eyes from five donors, photorecep

26 ociated with an increased hazard of incident exudative AMD (HR, 1.71; 95% CI, 1.04-2.82), but not pur

27 IMT, 1.31; CI, 1.05-1.64; P = 0.02) but not exudative AMD (OR per 0.1 mm IMT, 1.14; CI, 0.97-1.34; P

28 ssion to GA (OR 1.14; 95% CI, 1.07-1.21) and exudative AMD (OR, 1.08; 95% CI, 1.01-1.14).

29 ting for age, female sex was associated with exudative AMD (OR, 2.10; 95% CI, 1.10-3.98) and plasma H

30 Exudative AMD (wet AMD) is treated by monthly injection

31 ding 89 consecutive patients with unilateral exudative AMD and >/=3 years of followup.

32 ide association study on 2,119 patients with exudative AMD and 5,691 controls, with independent repli

33 tion was conducted to identify patients with exudative AMD and choroidal neovascularization (CNV) in

34 adults with no AMD, early AMD, and late AMD (exudative AMD and pure geographic atrophy) were 618.8 (1

35 e rates were calculated for nonexudative and exudative AMD and were stratified by Asian ethnicity.

36 use the Icon binds selectively to the CNV in exudative AMD as well as to laser-induced CNV, the Icon

37 In patients with bilateral exudative AMD at baseline, final vision at year 7 was si

38 a 5-year follow-up period were identified in exudative AMD beneficiaries newly diagnosed in 2006, the

39 ons of bevacizumab as the sole treatment for exudative AMD between September 2008 and October 2014 (n

40 those, there were 540 with and 4453 without exudative AMD diagnoses.

41 more effective therapeutic interventions for exudative AMD diffused rapidly throughout the United Sta

42 ng with the significantly thicker choroid in exudative AMD eyes before treatment initiation compared

43 The incidence of RVMA in exudative AMD eyes was significantly lower compared with

44 were no significant differences in risk for exudative AMD for any of the Asian ethnicities compared

45 elative risk for developing nonexudative and exudative AMD for persons of different Asian ethnicities

46 Fellow eyes with exudative AMD had received a mean 7.3 total injections o

47 ion of anti-VEGF agents in 2006 for treating exudative AMD has not posed a threat of increased risk o

48 nt group; beneficiaries newly diagnosed with exudative AMD in 2000 or nonexudative AMD in 2000 or 200

49 Beneficiaries with a first diagnosis of exudative AMD in 2006 were the treatment group; benefici

50 For the 35% of subjects with exudative AMD in both eyes at baseline, within-patient c

51 aser-induced CNV in a mouse model simulating exudative AMD in humans.

52 total of 23 941 Medicare beneficiaries with exudative AMD newly diagnosed during 1992-2009.

53 total of 23 941 Medicare beneficiaries with exudative AMD newly diagnosed during 1992-2009.

54 t this late stage in the therapeutic course, exudative AMD patients remain at risk for substantial vi

55 We found that DKK-1 levels were decreased in exudative AMD patients, compared with healthy controls (

56 For discriminating exudative AMD patients, the optimum diagnostic cutoff of

57 dosing of anti-VEGF therapy in patients with exudative AMD results in favorable long-term preservatio

58 le dementia was 1.35 (95% CI, 0.89-2.06) for exudative AMD versus the controls and 1.44 (95% CI, 1.26

59 The odds ratio (OR) of exudative AMD was 11.71 (95% CI; 5.24-6.13) for lowest v

60 eficiaries treated with anti-VEGF agents for exudative AMD was considerably greater than for prior in

61 Exudative AMD was uncommon among both probands and sibli

62 ive patients with unilateral treatment-naive exudative AMD were entered into the study over 6 months.

63 patients presenting with blurred vision and exudative AMD were imaged before and after anti-VEGF tre

64 We included 185 eyes of 141 patients with exudative AMD who were scheduled for their first treatme

65 11.0% pure geographic atrophy [GA] and 11.7% exudative AMD).

66 VMA (RVMA) was found in 15 (15.3%) eyes with exudative AMD, 21 (28.0%) eyes with nonexudative AMD, an

67 In patients with unilateral exudative AMD, 3 years of oral DHA-enriched supplementat

68 Plasma was obtained from 128 patients with exudative AMD, 46 patients with atrophic AMD and 111 hea

69 VMA was present in 101 (25.1%) eyes with exudative AMD, 84 (24.0%) eyes with nonexudative AMD, an

70 dual, 1 patient with dry AMD, 1 patient with exudative AMD, and 1 patient with nonproliferative diabe

71 ociated with the development and severity of exudative AMD, and have potential to become a biomarker

72 Unlike clinical trials for exudative AMD, it is impractical to use the change in vi

73 re geographic atrophy (GA), it was 0.6%; for exudative AMD, it was 0.9%; and for progression of AMD,

74 f the fellow eye of patients with unilateral exudative AMD, using a novel semiautomated grading syste

75 or treatment using proton beam radiation for exudative AMD.

76 uccess with VEGF inhibitors in patients with exudative AMD.

77 an important trigger for the progression of exudative AMD.

78 anti-VEGF treatment success in patients with exudative AMD.

79 >50 years and had angiographically verified exudative AMD.

80 4%) had nonexudative AMD and 217 (0.49%) had exudative AMD.

81 to identify enrollees with nonexudative and exudative AMD.

82 choroidal neovascularization, a hallmark of exudative AMD.

83 so be efficacious for treating patients with exudative AMD.

84 models and also on the CNV of patients with exudative AMD.

85 ad extrafoveal geographic atrophy, and 1 had exudative AMD.

86 and have potential to become a biomarker for exudative AMD.

87 RVMA over time was found in eyes affected by exudative AMD.

88 ith a 71% increase in the hazard of incident exudative AMD.

89 s a qualitative criterion for retreatment of exudative AMD.

90 ation; SD] age 77.8 [8.0] years) affected by exudative AMD; 350 eyes of 298 subjects (mean [SD] age 7

91 n, the CFH variant appears to play a role in exudative and atrophic disease, whereas the ELOVL4 varia

92 ts in stabilization of vision, resolution of exudative and hemorrhagic complications with regression

93 tases, abnormal choroidal vascular networks, exudative and hemorrhagic presentation) with polypoidal

94 The peripheral mass lesions were highly exudative and hemorrhagic, and usually associated with a

95 normal subjects and patients with untreated exudative and nonexudative AMD.

96 de spectrum of clinical phenotypes including exudative and nonexudative maculopathy was observed, wit

97 te retinal necrosis (ARN), which can lead to exudative and rhegmatogenous retinal detachment, yet lit

98 e mesangioproliferative, acute proliferative/exudative, and crescentic GN.

99 osis are (1) presence of erythematous-scaly, exudative, and crusted lesions involving >/=3 areas, inc

100 The treatment and management of exudative ARMD are changing dramatically.

101 68 years or older newly diagnosed as having exudative ARMD as indicated by beneficiaries having no c

102 erapy for patients 68 years or older with an exudative ARMD diagnosis in community-based settings in

103 T&E treatment protocol with ranibizumab for exudative ARMD in a 24-month period and suggests that su

104 ts of introducing new therapies for treating exudative ARMD on vision of the affected population and

105 ween beneficiaries newly diagnosed as having exudative ARMD who received photodynamic therapy or anti

106 ment efficiencies in patients suffering from exudative ARMD with a BCVA </= 0.05.

107 mong beneficiaries newly diagnosed as having exudative ARMD, the introduction of anti-VEGF therapy re

108 cted treatment naive patients diagnosed with exudative ARMD.

109 We found that lgtA in exudative bacteria is IF and that lgtC is OOF.

110 ce succumbed to a purulent multifocal severe exudative bronchopneumonia that closely resembles the di

111 In exudative cases, the success rate of laser treatment gui

112 attained are comparable to those observed in exudative cells.

113 onic lung lobes exhibiting fibronecrotic and exudative changes typical of pneumonic pasteurellosis, b

114 degeneration presenting with hemorrhagic and exudative changes within the macula and/or peripapillary

115 nd of year 2 that was not related to loss of exudative control.

116 ost TREX patients who demonstrated recurrent exudative disease activity (17/24 [71%]) were unable to

117 ain optical coherence tomography evidence of exudative disease activity; the interval between visits

118 he ELOVL4 variant may play a greater role in exudative disease in our population.

119 Active exudative disease was detected by spectral-domain OCT in

120 ed a grade ranging from 1 (no disease) to 5 (exudative disease).

121 diagnosed advanced AMD (geographic atrophy, exudative disease, or AMD causing visual loss) in one or

122 n lesion size enlargement is the duration of exudative disease.

123 ry received prompt treatment; 6 eyes without exudative features at study entry received deferred trea

124 Twenty-four eyes with exudative features at study entry received prompt treatm

125 study entry, gray lesion was associated with exudative features in 24 of 30 eyes (80%), including sub

126 Exudative features of myopic CNV are more obvious on FA

127 CNV was associated with exudative features on fluorescein angiography in 82% of

128 During fixed dosing (weeks 12-52) all exudative features showed synchronized fluctuations afte

129 With therapeutic intervention, exudative features such as IRC and SRF resolved rapidly

130 Exudative fellow eyes remained at risk for further visio

131 rea surrounding this cyst showed significant exudative fluid collection with diffuse, floating echoes

132 ysis, 4 (5%) eyes had complete resolution of exudative fluid, 40 (49%) showed partial resolution, 26

133 ined unchanged, and 12 (14%) showed worsened exudative fluid.

134 uman ascites fluid in vitro, an inflammatory exudative fluid.

135 of this disease, which closely resembles the exudative form of age-related macular degeneration.

136 , demonstrating a clear association with the exudative form of disease, thereby creating the possibil

137 ase and current treatment modalities for the exudative form of the disease require repeated intravitr

138 lost in NE-AMD as well as in the more severe exudative form, consistent with functional and clinical

139 sea, vomiting, and endoscopically documented exudative gastritis of the upper GI tract, which was dos

140 Peripheral exudative hemorrhagic chorioretinopathy shares many char

141 melanoma include choroidal nevus, peripheral exudative hemorrhagic chorioretinopathy, congenital hype

142 ies of 40 patients (48 eyes) with peripheral exudative hemorrhagic chorioretinopathy.

143 Effusions were exudative in 78% of the assessable cases.

144 sophagitis, with erosions or ulcerations and exudative inflammation accompanied by thickening of the

145 an influx of airway neutrophils and CD11b(+) exudative macrophages, which was reduced in TLR2(-/-) mi

146 y, threshold retinopathy of prematurity, and exudative macular degeneration appear to be especially c

147 up examination of pure geographic atrophy or exudative macular degeneration, any type of drusen with

148 he following: (1) laser photocoagulation for exudative macular degeneration; (2) laser treatment for

149 etinal fluid types across the most prevalent exudative macular diseases and OCT devices.

150 reflective intraretinal fluid across various exudative maculopathies.

151 corresponded to regions of SSPiM in several exudative maculopathies.

152 Eyes with various forms of exudative maculopathy including diabetic retinopathy (DR

153 e drusen, geographic atrophy, or evidence of exudative maculopathy were coded as affected for the pur

154 ix eyes in 62 patients with various forms of exudative maculopathy were evaluated; 60 eyes with DR, 9

155 ucing recombinant PGR/LTB(4)DH into a murine exudative model of inflammation increased PMN number by

156 Acute and subacute exudative, necrotizing lobar pneumonia characterized the

157 Human exudative neutrophils have greatly increased stores of t

158 ttractant that is elevated about 200-fold in exudative neutrophils isolated from localized inflammato

159 Since exudative neutrophils of wild-type mice expressed little

160 The exudative, or the wet form of age-related macular degene

161 bling the vitelliform lesions found in acute exudative paraneoplastic polymorphous vitelliform maculo

162 In its early exudative phase, neutrophil activation and accumulation

163 se paracrine mediators to the angiogenic and exudative phenotype of KS lesions remains unclear.

164 the differential diagnosis of an unexplained exudative pleural effusion, especially in an immunocompr

165 HU values can help in differentiating exudative pleural effusions from transudative pleural ef

166 ibe clinical findings in patients with acute exudative polymorphous vitelliform maculopathy (AEPVM).

167 Acute exudative polymorphous vitelliform maculopathy can prese

168 mpletely discriminate between pale, soft and exudative (PSE) and pale-only muscles.

169 in oxidation and the onset of pale, soft and exudative (PSE) condition in chicken breast are studied.

170 rbling score, rare occurrence of pale, soft, exudative (PSE) meat, but low growth rate and carcass we

171 which are strikingly similar to pale, soft, exudative (PSE) pork.

172 wing to the presence of ERM (10 eyes), large exudative RD (4 eyes), or vitreous hemorrhage (1 eye).

173 gnificantly increased for rhegmatogenous and exudative RD, with adjusted odds ratios of 1.41 (95% CI,

174 ytokine reserve seem to make the bulk of the exudative response resistant to CCR1 disruption.

175 ected by posterior uveal melanoma with large exudative retinal detachment (>10 mm in largest basal di

176 ected by posterior uveal melanoma with large exudative retinal detachment (>10 mm in largest basal di

177 r sheathing (aHR, 2.6, 95% CI, 1.4-4.9), and exudative retinal detachment (aHR, 4.1, 95% CI, 1.3-13).

178 hickness and largest basal diameter, largest exudative retinal detachment basal diameter, tumor locat

179 Marked exudative retinal detachment regression was documented i

180 Exudative retinal detachment resolution (B-scan ultrason

181 main outcome measure: Exudative retinal detachment resolution (B-scan ultrason

182 etonide injection induces earlier and marked exudative retinal detachment resolution after brachyther

183 raretinal and subretinal lipid accumulation (exudative retinal detachment).

184 Band keratopathy, >/= 3+ vitreous cells, exudative retinal detachment, posterior synechia, and a

185 rome with characteristic findings, including exudative retinal detachment, rapid cataract formation,

186 closure glaucoma, cystic macular edema, and exudative retinal detachment.

187 >grade 0; cataract; macular thickening; and exudative retinal detachment.

188 rom dermal and retinal vessels and prevented exudative retinal detachments in double-transgenic mice

189 ncluded patients presenting with symptomatic exudative retinal papillary capillary hemangioma with or

190 n develop in patients with NF1 and can cause exudative retinopathy, vitreous hemorrhage, and visual l

191 treatment (after 1 month observation), when exudative signs emerged (SRF in 3/6 eyes and retinal cys

192 ed that fibrin and vitronectin colocalize at exudative sites in which macrophages bearing these recep

193 ll consenting patients with chronic moist or exudative skin ulcers.

194 haracterised by a pale colour and grainy and exudative texture.

195 Patients usually present with an exudative tonsillitis, sore throat, dysphagia, and unila

196 lusion criteria included RRD before 2009 and exudative, tractional, or traumatic retinal detachments.

197 rshed zones that may be predictive of future exudative transformation.

198 Analyses of dry and exudative types of AMD and other alternative definitions

199 isk for RD, including the rhegmatogenous and exudative types.

200 Neisseria gonorrhoeae causes severe exudative urethritis.

201 e uncommon entity, referred to as perifoveal exudative vascular anomalous complex (PEVAC) by describi

202 elated vitreoretinopathies, such as familial exudative vitreoretinopathies including Norrie disease.

203 in vivo microstructural features of familial exudative vitreoretinopathy (FEVR) have not been well de

204 associated with autosomal dominant familial exudative vitreoretinopathy (FEVR) in families linking t

205 ating some pathological features of familial exudative vitreoretinopathy (FEVR) in human patients.

206 Familial exudative vitreoretinopathy (FEVR) is a genetically hete

207 Familial exudative vitreoretinopathy (FEVR) is a hereditary eye d

208 Familial exudative vitreoretinopathy (FEVR) is an inherited blind

209 Familial exudative vitreoretinopathy (FEVR) is an inherited blind

210 Familial exudative vitreoretinopathy (FEVR) is an inherited blind

211 Familial exudative vitreoretinopathy (FEVR) is characterized by d

212 l retina, typically associated with familial exudative vitreoretinopathy (FEVR), can result from muta

213 Participants with a diagnosis of familial exudative vitreoretinopathy (FEVR), Norrie disease, Coat

214 ornea, or a known family history of familial exudative vitreoretinopathy (FEVR), were also excluded.

215 n occurs in both Norrie disease and familial exudative vitreoretinopathy (FEVR).

216 are involved in the pathogenesis of familial exudative vitreoretinopathy (FEVR, MIM # 133780).

217 , ocular toxocariasis (n = 22; 4%), familial exudative vitreoretinopathy (FEVR; n = 18; 3%), rhegmato

218 ral retinal vasculitis (n = 4, 6%), familial exudative vitreoretinopathy (n = 3, 4%), and others (n =

219 uman retinopathy autosomal dominant familial exudative vitreoretinopathy and suggest that it also may

220 Familial exudative vitreoretinopathy has a wide range of unrecogn

221 hemorrhage and a female infant with familial exudative vitreoretinopathy.

222 sis, retinal hemangioblastomas, and familial exudative vitreoretinopathy.

223 uently mutated in Norrie disease or familial exudative vitreoretinopathy.

224 rs of signalling and are mutated in familial exudative vitreoretinopathy.

225 of central vision frequently occurs with the exudative (wet) form of AMD, as a result of the formatio